Lantus, a new long-acting insulin

June 2000

The FDA just approved Lantus, a new long-acting insulin.

It's longer acting than NPH or Ultralente...and doesn't produce peak concentrations like other insulins.

Lantus is a synthetic insulin called insulin glargine. It differs from human insulin by 3 amino acids.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote